H
HeyPsych
PsychTrails™TreatmentsConditionsResourcesFor CliniciansAbout

Stay updated on mental health treatments

Get the latest research, treatment updates, and evidence-based insights delivered to your inbox. No spam, just valuable mental health information.

Coming Soon

Newsletter subscription will be available soon.

H
HeyPsych

Evidence-based mental health treatment education platform. Helping you make informed decisions about your mental health journey.

Treatments

  • Medications
  • Interventional
  • Investigational
  • Alternative
  • Therapy
  • Supplements

Conditions

  • Depression
  • Anxiety
  • ADHD
  • Bipolar
  • All Conditions

Resources

  • Assessments & Screeners
  • Support & Community
  • Digital Tools
  • Knowledge Hub
  • PsychTrails™

Company

  • About Us
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 HeyPsych (PsychTrails™). All rights reserved.

Made with for better mental health
v2.2.0

Lormetazepam

Introduced 1980

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Indications

Primary Indications

Severe insomnia (short-term use)

Mechanism

Enhances the activity of GABA at the GABA-A receptor, increasing chloride influx and neuronal hyperpolarization, resulting in sedation and hypnosis.

Dosing

Adult Dosing

insomnia: 0.5–2 mg at bedtime; use the lowest effective dose

Dosage Forms

  • Tablets: 0.5 mg, 1 mg, 2 mg

Onset Duration

Onset: 30–60 minutes; Duration: 6–8 hours.

Adverse Effects

Common Side Effects

• drowsiness
• dizziness
• ataxia
• anterograde amnesia

⚠️ Serious Side Effects

  • respiratory depression
  • paradoxical agitation
  • dependence and withdrawal symptoms

Warnings

Critical Safety Information

Concomitant use with opioids can cause profound sedation, respiratory depression, coma, and death.
  • →Risk of misuse, abuse, and dependence
  • →Avoid abrupt discontinuation after prolonged use
  • →May cause next-day psychomotor impairment

Interactions

With: Opioids

Risk: Severe CNS depression

Action: Avoid or monitor closely

With: Alcohol

Risk: Additive sedation and respiratory depression

Action: Avoid

With: Other CNS depressants

Risk: Enhanced sedative effects

Action: Use caution

Monitoring

  • Daytime alertness
  • Signs of dependence and misuse
  • Respiratory status in at-risk patients

Special Populations

👶Pregnancy

Avoid unless absolutely necessary; risk of fetal harm and neonatal withdrawal

🤱Breastfeeding

Excreted in breast milk; may cause sedation in infants

👧Children & Adolescents (Under 18)

Not recommended

👴Older Adults (65+)

Increased sensitivity; start with lowest dose

Tapering

Reduce dose gradually over 1–2 weeks to avoid withdrawal symptoms such as rebound insomnia, anxiety, and tremors.

Clinical Notes

  • Short half-life reduces next-day sedation risk compared to longer-acting benzodiazepines
  • Best reserved for severe insomnia not responsive to non-pharmacologic interventions
  • High potential for dependence; avoid long-term use

This medication information is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Never take medication without a prescription from a licensed healthcare provider.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists